Dynamics and Correlates of CD8 T-Cell Counts in Africans with Primary Human Immunodeficiency Virus Type 1 Infection

Heather A. Prentice, University of Alabama at Birmingham
Hailin Lu, University of Alabama at Birmingham
Matthew A. Price, University of California at San Francisco
Anatoli Kamali, MRC/UVRI Uganda Virus Research Unit on AIDS
Etienne Karita, Project San Francisco
Shabir A. Lakhi, Emory University
Eduard J. Sanders, Kenya Medical Research Institute
Omu Anzala, Kenya AIDS Vaccine Initiative
Susan Allen, Emory University
Paul A. Goepfert, University of Alabama at Birmingham

Only first 10 authors above; see publication for full author list.

Journal Title: Journal of Virology
Volume: Volume 90, Number 22
Publisher: American Society for Microbiology | 2016-09-14, Pages 10423-10430
Type of Work: Article | Final Publisher PDF
Publisher DOI: 10.1128/JVI.01467-16
Permanent URL: https://pid.emory.edu/ark:/25593/s2jpb

Final published version: http://dx.doi.org/10.1128/JVI.01467-16

Copyright information:
© 2016, American Society for Microbiology. All Rights Reserved.
Accessed December 26, 2018 11:43 PM EST
Dynamics and Correlates of CD8 T-Cell Counts in Africans with Primary Human Immunodeficiency Virus Type 1 Infection

Heather A. Prentice, a,b* Hallin Lu, a Matthew A. Price, a,c Anatoli Kamali, a Etienne Karita, a Shabir Lakhi, f Eduard J. Sanders, a,b Omu Anzala, i Susan Allen, a,e,f,g Paul A. Goepfert, a Eric Hunter, a Jill Gilmour, a Jianming Tang, a for the International AIDS Vaccine Initiative African HIV Research Network

Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA; International AIDS Vaccine Initiative, New York, New York, USA; Department of Epidemiology and Biostatistics, University of California at San Francisco, San Francisco, California, USA; MRC/Uganda Virus Research Unit on AIDS, Masaka Site, Masaka, Uganda; Project San Francisco, Kigali, Rwanda; Zambia-Emory HIV Research Project, Lusaka, Zambia; Centre for Geographic Medicine Research, Kenya Medical Research Institute, Kilifi, Kenya; Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Headington, United Kingdom; Kenya AIDS Vaccine Initiative, Nairobi, Kenya; Department of Pathology and Laboratory Medicine, Emory University, Atlanta, Georgia, USA; Vaccine Research Center, Emory University, Atlanta, Georgia, USA; International AIDS Vaccine Initiative, Human Immunology Laboratory, Chelsea and Westminster Hospital, London, United Kingdom

ABSTRACT

In individuals with HIV-1 infection, depletion of CD4+ T cells is often accompanied by a malfunction of CD8+ T cells that are persistently activated and/or exhausted. While the dynamics and correlates of CD4 counts have been well documented, the same does not apply to CD8 counts. Here, we examined the CD8 counts in a cohort of 497 Africans with primary HIV-1 infection evaluated in monthly to quarterly follow-up visits for up to 3 years in the absence of antiretroviral therapy. Statistical models revealed that (i) CD8 counts were relatively steady in the 3- to 36-month period of infection and similar between men and women; (ii) neither geography nor heterogeneity in the HIV-1 set-point viral load could account for the roughly 10-fold range of CD8 counts in the cohort (P > 0.25 in all tests); and (iii) factors independently associated with relatively high CD8 counts included demographics (age ≤ 40 years, adjusted P = 0.010) and several human leukocyte antigen class I (HLA-I) alleles, including HLA-A*03:01 (P = 0.013), B*15:10 (P = 0.007), and B*58:02 (P < 0.001). Multiple sensitivity analyses provided supporting evidence for these novel relationships. Overall, these findings suggest that factors associated with the CD8 count have little overlap with those previously reported for other HIV-1-related outcome measures, including viral load, CD4 count, and CD4/CD8 ratio.

IMPORTANCE

Longitudinal data from 497 HIV-1 seroconverters allowed us to systematically evaluate the dynamics and correlates of CD8+ T-cell counts during untreated primary HIV-1 infection in eastern and southern Africans. Our findings suggest that individuals with certain HLA-I alleles, including A*03 (exclusively A*03:01), persistently maintain relatively high CD8 counts following HIV-1 infection, a finding which may offer an intriguing explanation for the recently reported, negative association of A*03 with HIV-1-specific, broadly neutralizing antibody responses. In future studies, attention to HLA-I genotyping data may benefit in-depth understanding of both cellular and humoral immunity, as well as the intrinsic balances of these types of immunity, especially in settings where there is emerging evidence of antigenic between the two arms of adaptive immunity.

CD8+ cytotoxic T lymphocytes (CTLs) are critical to early immune control of HIV-1 infection, and many studies have documented the dynamics and evolution of HIV-1-specific CTLs that target viral epitopes in the context of differential presentation (restriction) by the highly variable human leukocyte antigen class I (HLA-I) molecules (1–5). More often than not, the immune protection provided by CTLs is transient, as CTL escape mutations are abundant in the circulating viruses, even in the presence of favorable HLA-I variants like B*57 and B*81 (6–8). Concomitantly, depletion of CD4+ helper T cells can exacerbate the losing battle for CTLs, leading to the accumulation of activated and exhausted CD8 cells (9–13), as well as a persistent reversion of the CD4/CD8 T-lymphocyte ratio (14–16). Moreover, the orchestration of cellular and humoral immunity can be problematic when CTL impairment occurs early, as broadly neutralizing antibodies usually take years to develop (17–19).

In the clinical realm, attention to the dynamics and functions of CD8 cells per se has been rather limited, as much of the decision-making process relies almost exclusively on the HIV-1 viral load (VL) and CD4+ T-cell (CD4) counts following diagnosis of HIV-1 infection. However, the new era of early and intensified antiretroviral therapy (ART) is likely to change this paradigm for three reasons. First, the CD4 count alone is unable to fully gauge immunologic health after ART (20–22). Second, CD8 cells are essential to the eradication of residual HIV-1 reservoirs after ART initiation (23–26). Third, CD8 cells can be induced to enhance the efficacy of vaccination (27), as reported recently in nonhuman primate models (28, 29). To this end, it is worthwhile to take a step back...
and examine the dynamics and correlates of CD8 counts before ART initiation, especially in regions where such data remain sparse.

Our findings, based on evaluations of 497 HIV-1-infected Africans with multiple pre-ART visits, now suggest that the independent correlates of the CD8 count have little overlap with those previously seen with the set-point VL, CD4 count, and CD4/CD8 ratio. The underlying biology deserves further investigation and may have implications beyond cellular immunity.

MATERIALS AND METHODS

Study population, laboratory techniques, and outcome measures. Our work here focused on 497 HIV-1 seroconverters (SCs) from Kenya, Rwanda, Uganda, and Zambia who were enrolled under a uniform study protocol developed and implemented by the International AIDS Vaccine Initiative (IAVI). The study design and research procedures, including written informed consent and laboratory testing (e.g., viral sequencing and HLA genotyping), were approved by the institutional review boards at IAVI, Emory University, and the University of Alabama at Birmingham. Clinical and laboratory tests, including centralized, T-cell immunophenotyping during monthly to quarterly follow-up visits, have been described in detail elsewhere (16, 30–33). ART initiation followed appropriate national guidelines (34), but post-ART data were too sporadic (limited to 56 person visits) to allow meaningful analysis. To facilitate a direct comparison with earlier statistical models for establishing correlates of the set-point VL, CD4 count, and CD4/CD8 ratio in primary HIV-1 infection (16, 32, 33), the SCs included in this study must have had at least three virologic and immunologic outcome measures in the 3- to 24-month period after the estimated date of infection (EDI). In addition, all SCs had fully resolved HLA-I genotypes, as also reported earlier (16, 32, 33).

Statistical analysis. Using software packages in SAS, version 9.4 (SAS Institute, Cary, NC), data analyses focused on pre-ART CD8 counts, with further consideration being given to earlier work that analyzed the pre-ART VL, CD4 count, and CD4/CD8 ratio (16, 32, 33). We began with a full assessment of log10-transformed CD8 counts in the 3- to 36-month period after EDI, using Pearson’s correlation coefficients (r), local regression (LOESS) curves, mixed models for repeated measurements, analysis of variance (ANOVA) of cross-sectional data (i.e., visit-specific data or mean CD8 counts over a given time period), and logistic regression models for cross-sectional data. Association analyses targeted HLA variants that were adequately prevalent (present in ≥5% of the study population), with a focus being on individual alleles that met two thresholds of statistical significance, i.e., a P value of <0.05 and a q value of <0.10. Summary statistics included (i) P values and associated false discovery rates (FDR; q values) when multiple testing was applied and (ii) the effect size of individual factors on the CD8 count, as measured by mean regression beta estimates (β), the standard error (SE) of β, and the degree of variance explained by each factor (R²). In multivariable models, statistical adjustments were made for demographics (sex and age), geography (eastern versus southern Africa), and three categories (low, medium, and high) of the set-point VL that have clinical and epidemiological implications (32).

The final statistical models were also subjected to sensitivity analyses that were restricted to data from the 3- to 24-month period after EDI. For individual correlates of the CD8 count (with log10 transformation), the statistical significance was accepted at the level of a P value of <0.05 and a q value of <0.10 in the initial screening models, followed by an adjusted P value of <0.05 in multivariable tests.

Bioinformatics. Several public databases were surveyed for further evidence of genomics data pertinent to HLA/major histocompatibility complex (MHC) gene expression and effective tagging of individual HLA alleles by single nucleotide polymorphisms (SNPs). Specifically, MHC SNPs that tag HLA class I alleles in Africans (35) were first queried in HaploReg, version 4.0 (http://www.broadinstitute.org/ mammals/haploreg/haploreg_v4.php, last accessed on 2 September 2016) (36) for patterns of linkage disequilibrium (LD) uncovered by The 1000 Genomes Project and for functional properties annotated by the ENCODE project (37, 38). SNPs already associated with immune disorders and/or gene expression quantitative trait loci (eQTLs) (39) were checked in the NCBI Global Cross database (http://www.ncbi.nlm.nih.gov/) and the SCAN database (http://www.scandb.org/newinterface/index.html, last accessed on 11 March 2016). Findings on HLA-I variants were interpreted in light of these bioinformatics data, with further reference being made to a panel of fine-mapped, causal SNPs linked to various genome-wide association studies (40).

RESULTS

Steady CD8 counts in 497 SCs. In the 3 to 36 months after EDI, CD8 counts were available for a total of 4,131 person visits. Overall, CD8 counts ranged from 2.40 to 3.30 log10 (a roughly 10-fold range), being relatively stable within individuals and similar between 185 women and 312 men (P > 0.60) (Fig. 1). For example, the linear correlation between the first CD8 count after 3 months of infection and the last count before 36 months was quite strong for both men (Pearson r = 0.77, P < 0.0001) and women (r = 0.78, P < 0.0001). Evaluation of other demographic features revealed that longitudinal CD8 counts differed between individuals...
in two age groups (P = 0.027 for individuals >40 years old versus individuals ≤40 years old) but were similar between individuals from eastern and southern Africa (P = 0.47). Differences between age groups were confirmed by analysis of the mean CD8 counts (with log10 transformation) during the 3- to 36-month intervals (P = 0.018) (Fig. 2).

**HLA variants as genetic correlates of CD8 counts.** In the study cohort, 12 HLA-A, 16 HLA-B, and 9 HLA-C variants had to be observed in at least 25 (5%) individuals to facilitate statistical screening for potential associations with repeated measures of CD8 counts (Table 1). After statistical adjustments for potential confounding by age, sex, geography, and duration of HIV-1 infection, individual alleles that met the thresholds of statistical significance included A*03 (exclusively A*03:01) (Δ = 0.08 ± 0.03, P = 0.003, q = 0.048), B*15:10 (Δ = 0.06 ± 0.02, P = 0.005, q = 0.059), and B*58:02 (Δ = 0.07 ± 0.02, P < 0.001, q = 0.015). The only variant that appeared to have a negative impact on CD8 counts was B*58:01, but the borderline statistical significance (P = 0.049) had a high probability of false discovery (q = 0.394) (Table 1).

Visualization using LOESS curves indicated steady differences between subjects with and without these HLA variants (e.g., for the A*03-positive [A*03+] versus A*03-negative [A*03−] groups in Fig. 3). In multivariable models, all three genetic correlates were independent of other potential confounders (adjusted P-value range, <0.001 to 0.013) (Table 2). An alternative model for mean CD8 counts led to almost identical results for the HLA variants of interest (adjusted P-value range, <0.001 to 0.013) (Table 2). In contrast, both statistical models failed to detect differences in CD8 counts that could be attributed to the three HIV-1 VL groups (adjusted P-value range, 0.251 to 0.795).

**Supporting evidence from sensitivity analyses.** When analyses were restricted to the 3- to 24-month period after EDI, the multivariable model for repeated outcome measurements (3,440 person visits) also supported the independent associations between CD8 counts and A*03 (adjusted Δ = 0.06 ± 0.03, P = 0.019), B*15:10 (adjusted Δ = 0.07 ± 0.02, P = 0.003), and B*58:02 (adjusted Δ = 0.07 ± 0.02, P < 0.001) (Table 3), as did the alternative model for mean CD8 counts (adjusted P-value range, < 0.001 to 0.019 as well) (Table 3). Again, the variance in mean CD8 counts was not attributable to distinct VI groups (adjusted P-value range, 0.340 to 0.527).

**No clear additive effects of three HLA factors.** In the study cohort, 26 SCs had a combination of A*03, B*15:10, and B*58:02. The mean CD8 counts over the 3- to 36-month intervals were found to be the highest in this small subgroup when the counts were compared with those in SCs with a single HLA factor and the reference group (all others) without any HLA variants of interest (Fig. 4) (P < 0.0001 by ANOVA), but the difference between the first two subgroups was modest (P = 0.281 by t test). The mean CD8 counts over the 3- to 24-month intervals yielded similar results (P = 0.272 for multiple alleles versus a single allele).

**Findings based on bioinformatics.** In populations of African ancestry (35), HLA-A*03:01 is known to be tagged by rs2524024, a SNP that is distant (30 kb away) from the 5’ end of HLA-A, while B*15:10 is tagged by two SNPs, rs3819294 (an HLA-B intronic SNP) and rs2523638 (a SNP between DHRFP2 and MICA). These SNPs are also in strong LD with multiple neighboring variants, including eQTLs associated with gene expression profiles in Afri-

![FIG 2 Mean CD8 counts in HIV-1 seroconverters defined by two age groups.](image-url)
Table 2: Correlates of CD8 counts in 497 HIV-1 SCs revealed by two multivariable models

<table>
<thead>
<tr>
<th>Individual factors in each model</th>
<th>For repeated measurements(^a)</th>
<th>For mean CD8 counts(^a)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (\geq 40) ((n = 75)) vs (&lt; 40) ((n = 422))</td>
<td>(-0.05 \pm 0.02) 0.010</td>
<td>(-0.05 \pm 0.02) 0.007</td>
</tr>
<tr>
<td>Women ((n = 185)) vs men ((n = 312))(^b)</td>
<td>0.00 \pm 0.02 0.913</td>
<td>0.00 \pm 0.02 0.915</td>
</tr>
<tr>
<td>Zambia (southern Africa, (n = 195))(^b,c)</td>
<td>(-0.01 \pm 0.01) 0.660</td>
<td>(-0.01 \pm 0.02) 0.685</td>
</tr>
<tr>
<td>Low VL ((n = 140))(^d)</td>
<td>(-0.01 \pm 0.02) 0.588</td>
<td>(-0.00 \pm 0.02) 0.795</td>
</tr>
<tr>
<td>High VL ((n = 92))(^d)</td>
<td>(-0.02 \pm 0.02) 0.251</td>
<td>(-0.01 \pm 0.02) 0.517</td>
</tr>
<tr>
<td>Duration of infection (per quarter)</td>
<td>(-0.07 \pm 0.01) &lt;0.0001</td>
<td>NA</td>
</tr>
</tbody>
</table>

\(^a\) CD8 counts in the 3- to 36-month period after the estimated date of infection with \(\log_{10}\) transformation. NA, not applicable.

\(^b\) For consistency with earlier reports, these factors were retained in the models because they were associated with the HIV-1 viral load and CD4 counts in the same cohort.

\(^c\) Compared with subjects from other countries in eastern Africa \((n = 302)\).

\(^d\) The three HIV-1 VL categories are defined as low \((<10^4\) RNA copies/ml\), medium \((10^4 \text{ to } 10^5\) RNA copies/ml\), and high \((>10^5\) RNA copies/ml\), according to their differential impact on HIV-1 transmission and disease progression \((7, 37)\), with the medium VL \((n = 263)\) being the reference group for comparison.

Table 3: Sensitivity analyses of two multivariable models for CD8 counts in the 3- to 24-month period after EDI

<table>
<thead>
<tr>
<th>Individual factors in each model</th>
<th>For repeated measurements(^a)</th>
<th>For mean CD8 counts(^a)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (\geq 40) ((n = 75)) vs (&lt; 40) ((n = 422))</td>
<td>(-0.05 \pm 0.02) 0.010</td>
<td>(-0.05 \pm 0.02) 0.008</td>
</tr>
<tr>
<td>Women ((n = 185)) vs men ((n = 312))(^b)</td>
<td>0.01 \pm 0.02 0.721</td>
<td>0.01 \pm 0.02 0.725</td>
</tr>
<tr>
<td>Zambia (southern Africa, (n = 195))(^b,c)</td>
<td>(-0.01 \pm 0.02) 0.532</td>
<td>(-0.01 \pm 0.02) 0.541</td>
</tr>
<tr>
<td>Low VL ((n = 140))(^d)</td>
<td>(-0.01 \pm 0.02) 0.527</td>
<td>(-0.01 \pm 0.02) 0.497</td>
</tr>
<tr>
<td>High VL ((n = 92))(^d)</td>
<td>(-0.02 \pm 0.02) 0.340</td>
<td>(-0.02 \pm 0.02) 0.384</td>
</tr>
<tr>
<td>Duration of infection (per quarter)</td>
<td>(-0.07 \pm 0.01) &lt;0.0001</td>
<td>NA</td>
</tr>
</tbody>
</table>

\(^a\) See footnote \(a\) of Table 2.

\(^b\) See footnote \(b\) of Table 2.

\(^c\) See footnote \(c\) of Table 2.

\(^d\) See footnote \(d\) of Table 2.

Figure 3: Local regression curves for CD8 counts in seroconverters with and without HLA-A*03 (3 to 36 months after the estimated date of HIV-1 infection). For each stratum (presence and absence of A*03), solid and dotted lines correspond to the mean values and 95% confidence intervals, respectively.

Figure 4: Lack of additive effect of HLA variants on CD8 counts. The mean CD8 counts (3 to 36 months after the estimated date of HIV-1 infection) in three subgroups of HIV-1 seroconverters were compared on the basis of the presence and absence of three HLA variants of interest (A*03, B*15:10, and B*58:02). Heterogeneity among the three groups is evident \((P < 0.001\) for the overall comparison).
starkly from those of two other commonly studied outcomes, i.e., the HIV-1 VL and CD4 T-cell counts. First, unlike the VL and CD4 counts, which often differ by sex and geography (a proxy for viral subtypes) (32, 33, 47), CD8 counts and their trajectories during primary HIV-1 infection are similar between men and women and between eastern and southern Africans, which can substantially simplify the search for generalizable and biological correlates using aggregated (instead of stratified) data (47). Second, despite their narrow ranges, log10-transformed CD8 counts are informative quantitative traits for various statistical modeling, as multiple factors associated with CD8 counts can be established. Third, HLA variants (A*03:01, B*15:10, and B*58:02) associated with CD8 counts have little or no overlap with those (e.g., B*18, B*45, B*53, B*57, and B*81) previously reported for VL and CD4 counts in the same study cohort (32, 33, 47), suggesting that the underlying mechanisms should be distinct and may even precede HIV-1 infection (i.e., through intrinsic functions). Analyses of similar data from other cohorts should facilitate a better understanding of CD8 T-cell function in HIV-1 infection and in general populations (45).

Although they were statistically significant in the overall analyses and robust in sensitivity models, the effects of three HLA variants on CD8 counts were all relatively modest during the study. The biological consequences may depend on the longevity of these seemingly minor differences and the subsets of CD8 T cells that are mostly affected. Earlier research has suggested that steady CD8 T-cell counts during chronic HIV-1 infection may reflect a prolonged differentiation rather than increased activation (9). This long-lasting phenomenon may indirectly impair other arms of immune responses, at least in individuals with HLA-A*03 (exclusively A*03:01 in the study cohort) because this allele is enriched in subjects who did not develop HIV-1-specific, broadly neutralizing antibody responses (48). Assuming that antagonism and competition do exist between the cellular and humoral arms of adaptive immunity, especially in lymphoid tissues, where both space and resources are limited (49, 50), one can also envision that HLA alleles B*15:10 and B*58:02 may operate in a similar fashion. Meta-analyses of data from different studies should offer new insights into this new hypothesis. Indeed, a recently reported association between HLA-A*02 and enhanced humoral (IgG) responses to HIV-1 vaccination (the RV144 trial in Thailand) (51) may be viewed as anecdotal evidence for this hypothesis, although it is still not clear if such conclusions can apply to various populations that differ in HLA-I allelic profiles and/or allele frequencies.

Previously, a genome-wide association study (45) identified a single SNP (rs2524054) to be a major correlate of CD8 counts in healthy adolescent twins from Australia (effect size = −0.31 ± 0.03 log10). Located between HLA-C and HLA-B, rs2524054 has some functional attributes (gene expression patterns), but there is no indication that rs2524054 tags specific HLA-I alleles (35) or SNPs (rs2524024, rs3819294, and rs2525638) that are in strong LD with A*03:01 and B*15:10. Recent fine-mapping data do suggest that LD between rs2524054 and a functional (causal) SNP variant (rs2247056-T) can account for the association of rs2524054 with serum triglycerides in healthy subjects (40). Although fine mapping can be influenced by ethnic backgrounds, a focus on gene expression and lipid metabolism is expected to expedite future research on immunogenetic control of the CD8 T-cell function in health and diseases.

On the other hand, the positive impact of B*58:02 on CD8 counts is not complicated by neighboring SNPs (35). In several studies of HIV-1-infected Africans (52–54), B*58:02 has been recognized to be unfavorable (associated with a high viral load and low CD4 counts), being functionally and epidemiologically distinct from another closely related allele, B*58:01 (52–54). By our analysis, B*58:01 and B*58:02 do seem to have opposing impacts on CD8 counts, but the statistical power in our study favors the analysis of B*58:02 rather than B*58:01 (which were found in 72 versus 55 subjects, respectively, in our cohort). A more definitive conclusion will obviously require a larger sample size to strengthen the analysis of B*58:01.

One major limitation in this study is the lack of CD8 count data before HIV-1 infection and after ART initiation. As our study cohort was designed for the evaluation of primary HIV-1 infection, preinfection and post-ART data from other study populations will help assess the relationships between HLA-I alleles and the dynamics of CD8 counts in Africans. For example, a hematology reference panel has included CD8 counts in 2,105 healthy subjects from eastern and southern Africa (55). Preparation for vaccine trials may justify HLA-I genotyping in this large study population. Meanwhile, assembling a prospective post-ART data set will likely require years of concerted efforts, as the implementation of new guidelines for early HIV-1 therapy has been a slow process.

The frequencies of HLA-I alleles being highlighted in this study ranged from 9% to 14% in our study cohort (Table 1). Collectively, they were found in over 29% of subjects (Fig. 4). The distribution of these alleles in other ethnic groups can vary, but A*03:01 is a globally common allele and should be readily analyzed in other cohorts, including general populations where CD8 T-cell counts are measured (45, 55). Overall, our findings should broaden the attention to immunogenetic factors, since variability in CD8 counts before antiretroviral therapy may relate to the function of multiple HLA-I variants. This concept can be equally pertinent to studies of CD8 T-cell function after antiretroviral therapy (56).

ACKNOWLEDGMENTS

We thank all members of the IAVI African HIV Research Network for their valuable contributions to cohort assembly and data collection. We are also grateful to several associates, especially Travis Porter and Xuelin Li, for technical assistance.

This work was funded in part by IAVI and made possible by the generous support from many donors, including the Bill & Melinda Gates Foundation, the Ministry of Foreign Affairs of Denmark, Irish Aid, the Ministry of Finance of Japan, the Ministry of Foreign Affairs of the Netherlands, the Norwegian Agency for Development Cooperation, the United Kingdom Department for International Development, and the United States Agency for International Development (USAID). The full list of IAVI donors is available at www.iavi.org. Additional funding for this work came from (i) the United States National Institute of Allergy and Infectious Diseases (NIAID) through an R01 grant (AI064060 to E.H., P.A.G., and J.T.), (ii) the Fogarty AIDS International Training and Research Program (AITRP) (grant RIC 2D43 TW001042 to S.L.), and (iii) the KEMRI-Wellcome Trust Research Programme at the Centre for Geographical Medicine Research-Kilifi (Wellcome Trust award 077092).

Submission of this work for publication required approval by the director of the Kenya Medical Research Institute (KEMRI) and by KEMRI and IAVI representatives, but the contents are the responsibility of the
individual authors and do not necessarily reflect the views of IAVI, KEMRI, NIAID, USAID, or the United States government.

FUNDING INFORMATION

This work, including the efforts of Eric Hunter, Paul A. Goepfert, and Jianming Tang, was funded by NIAID (R01 AI064060). This work, including the efforts of Shabir Lakh, was also funded in part by NITR (FIC 2D43 TW001042).

REFERENCES


